Monopar Therapeutics is a biopharmaceutical firm in early development stages that focuses on oncology treatments. The company's pipeline includes ALXN1840, an oral candidate for Wilson disease developed under a licensing arrangement with Alexion, and several variants of MNPR-101, a humanized antibody designed to target tumors that express urokinase plasminogen activator receptor, with formulations in imaging and radiotherapy applications currently in clinical trials. The firm, based in Illinois and founded in 2014, maintains partnerships to advance its radiotherapeutic and diagnostic programs.
1Y: 70.32 (-18.4%) · range 50.12–123.84
entry readiness 87 · STRONG SETUP · exit proximity 0
Value area 76.81–124.82 · 79% of 120d volume overhead · heavy supply
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -4.30% | +7.78% | mature |
| 40d | -26.91% | +7.78% | mature |